FDA approves daraxonrasib for pancreatic cancer

The FDA approved daraxonrasib for adults with metastatic pancreatic cancer who have had at least one prior systemic treatment or cannot receive multi-drug systemic treatment.

What this means. A large, final-stage trial in pancreatic cancer. This is the kind of result regulators use when deciding whether to approve a treatment.

In vivo immune-cell therapy had mixed results in multiple myeloma

Among four patients with multiple myeloma treated with immune cells modified inside the body, responses lasted only a short time in three. One patient’s response lasted 15 months.

What this means. Lab or animal research on myeloma, a blood cancer. Not yet tested as a treatment in people; many lab results never reach patients.

Glofitamab combination led to complete responses in diffuse large B-cell lymphoma

In a phase II trial, 41 people with newly diagnosed diffuse large B-cell lymphoma received glofitamab with polatuzumab-based chemotherapy. 39 of 41 had a complete response.

“These data support further evaluation of this regimen.”

What this means. A mid-stage trial in lymphoma, a blood cancer. Good results at this stage usually still need a larger trial before approval.

Cryotherapy tested to prevent nerve damage during taxane cancer treatment

A randomized trial tested cryotherapy to prevent nerve damage from taxane chemotherapy. The source gives no trial results.

What this means. A trial in cancer that split people into groups at random, the fairest kind of test.

Lab-grown kidney models reveal origins of Wilms tumor

Researchers used models made from human fetal kidney tissue to test cancer-related changes. Some changes and combinations caused tumor-like growth, and the team linked them to specific kidney cell lineages.

What this means. Lab or animal research on kidney cancer. Not yet tested as a treatment in people; many lab results never reach patients.